Orlistat - Selective inhibition of caloric absorption can affect long-term body weight

被引:20
作者
Hauptman, J [1 ]
机构
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
关键词
orlistat; antiobesity agents; fat-restricted diet; weight loss; coronary risk;
D O I
10.1385/ENDO:13:2:201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orlistat is a novel, noncentrally acting antiobesity agent that selectively inhibits gastrointestinal lipase activity, thereby reducing the absorption of dietary fat by approximately one-third. In a series of 1- and 2-yr randomized, placebo-controlled trials of obese subjects, treatment with orlistat in combination with a mildly calorie-restricted diet consistently produced significantly greater mean weight loss than diet alone. More orlistat-treated subjects than placebo recipients achieved clinically meaningful weight reduction (greater than or equal to5% or greater than or equal to 10% of initial body weight) after 1 and 2 yr. Orlistat was also associated with a significant reduction in the regain of lost weight during long-term treatment. In addition, orlistat therapy resulted in significant improvements in several cardiovascular risk factors including serum total and low-density lipoprotein-cholesterol, serum insulin levels, systolic and diastolic blood pressure, and waist circumference. Furthermore, obese subjects with type 2 diabetes achieved a significantly greater decrease in body weight with orlistat compared with placebo, as well as significant improvements in HbA(1c) and fasting glucose levels. Among subjects with impaired glucose tolerance, orlistat compared with placebo reduced the proportion who developed type 2 diabetes. Conversely, orlistat increased the proportion of subjects who achieved a normalization of glucose tolerance. Orlistat acts locally in the gastrointestinal tract and is only minimally absorbed. In long-term clinical trials, orlistat was well tolerated by both diabetic and nondiabetic subjects.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 43 条
[1]   SHORT-TERM ENERGY-BALANCE - RELATIONSHIP WITH PROTEIN, CARBOHYDRATE, AND FAT BALANCES [J].
ABBOTT, WGH ;
HOWARD, BV ;
CHRISTIN, L ;
FREYMOND, D ;
LILLIOJA, S ;
BOYCE, VL ;
ANDERSON, TE ;
BOGARDUS, C ;
RAVUSSIN, E .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (03) :E332-E337
[2]  
[Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[3]   Modern medical management of obesity: The role of pharmaceutical intervention [J].
Aronne, LJ .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1998, 98 (10) :S23-S26
[4]   FAILURE TO INCREASE LIPID OXIDATION IN RESPONSE TO INCREASING DIETARY-FAT CONTENT IN FORMERLY OBESE WOMEN [J].
ASTRUP, A ;
BUEMANN, B ;
CHRISTENSEN, NJ ;
TOUBRO, S .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (04) :E592-E599
[5]  
ASTRUP A, 1999, INT J OBES S5, V23, pA304
[6]   High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study [J].
Balkau, B ;
Shipley, M ;
Jarrett, RJ ;
Pyörälä, K ;
Pyörälä, M ;
Forhan, A ;
Eschwège, E .
DIABETES CARE, 1998, 21 (03) :360-367
[7]  
BLUNDELL JE, 1993, AM J CLIN NUTR, V57, P772
[8]   Dietary fat intake does affect obesity! [J].
Bray, GA ;
Popkin, BM .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (06) :1157-1173
[9]   OBESITY, FAT DISTRIBUTION, AND WEIGHT-GAIN AS RISK-FACTORS FOR CLINICAL DIABETES IN MEN [J].
CHAN, JM ;
RIMM, EB ;
COLDITZ, GA ;
STAMPFER, MJ ;
WILLETT, WC .
DIABETES CARE, 1994, 17 (09) :961-969
[10]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242